SLS supply chain intelligence for SELLAS Life Sciences Group, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
SELLAS Life Sciences Group, Inc. (SLS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONSULTANTS | CONSULTANTS | 90% | expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials |
| CROS | CROS | 90% | expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials |
| INVESTIGATIVE-SITES | INVESTIGATIVE-SITES | 90% | expenses incurred under agreements with CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| 3D-MEDICINES | 3D-MEDICINES | 92% | The Company evaluated the 3D Medicines Agreement under ASC Topic 606, Revenue From Contracts with Customers, and recognized an initial transaction price of $ 9.5 million, which included the $ 7.5 mil… |
| NVAX | Novavax, Inc. | 92% | Reciprocal relationship from NVAX graph: Reciprocal relationship from SLS graph: Reciprocal relationship from NVAX graph: Reciprocal relationship from SLS graph: Reciprocal relationship from NVAX gra… |
| MRK | Merck & Co., Inc. | 72% | dose cohort in the Phase 2a study and reported positive initial topline data. At that time, we also commenced enrollment in the 60 mg dose cohort with patients randomized to one of two groups, 60 mg … |
| MRK | Merck & Co., Inc. | 72% | Reciprocal relationship from MRK graph: Reciprocal relationship from SLS graph: dose cohort in the Phase 2a study and reported positive initial topline data. At that time, we also commenced enrollmen… |
| SLSG-LIMITED-LLC | SLSG-LIMITED-LLC | 62% | our Phase 2 clinical trial for SLS009 in newly diagnosed, front-line AML patients. General and Administrative General and administrative expenses were $4.1 million for the three months ended March 31… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| SLS-DEBT-12598 | Warrants outstanding: 818900 | 90% | xbrl warrant detail from xbrl 2026-03-31. |
| SLS-DEBT-12599 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2017-12-31. |
| SLS-DEBT | Debt stack $871,000 | 90% | Market cache reports total debt of $871,000. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| SLS-OWNER-DAGCO-INC | Dagco, Inc. | 95% | 13F/ownership overlay lists Dagco, Inc.; shares held 1,028,780; ownership 0.56%; value $5.3M; as of 2026-03-31. |
| SLS-OWNER-MARSHALL-WACE-LLP | Marshall Wace LLP | 95% | 13F/ownership overlay lists Marshall Wace LLP; shares held 1,340,668; ownership 0.73%; value $6.9M; as of 2025-12-31. |
| SLS-OWNER-STATE-STREET-CORPORATION | State Street Corporation | 95% | 13F/ownership overlay lists State Street Corporation; shares held 2,188,171; ownership 1.19%; value $11.3M; as of 2025-12-31. |
| SLS-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 3,077,337; ownership 1.67%; value $15.8M; as of 2025-12-31. |
| SLS-OWNER-TWO-SIGMA-INVESTMENTS-LP | Two Sigma Investments, LP | 95% | 13F/ownership overlay lists Two Sigma Investments, LP; shares held 1,082,207; ownership 0.59%; value $5.6M; as of 2025-12-31. |
| SLS-OWNER-BLACKROCK-INC | Blackrock Inc. | 95% | 13F/ownership overlay lists Blackrock Inc.; shares held 7,541,054; ownership 4.09%; value $38.8M; as of 2025-12-31. |
| SLS-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 890,929; ownership 0.48%; value $4.6M; as of 2025-12-31. |
| SLS-OWNER-NORTHERN-TRUST-CORPORATION | Northern Trust Corporation | 95% | 13F/ownership overlay lists Northern Trust Corporation; shares held 930,750; ownership 0.50%; value $4.8M; as of 2025-12-31. |
| SLS-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 8,467,400; ownership 4.59%; value $43.6M; as of 2025-12-31. |
| SLS-OWNER-MILLENNIUM-MANAGEMENT-LLC | Millennium Management Llc | 95% | 13F/ownership overlay lists Millennium Management Llc; shares held 1,387,849; ownership 0.75%; value $7.1M; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| MRK | Merck & Co., Inc. | 100.00 | 1 | ['customer'] |
| NVAX | Novavax, Inc. | 100.00 | 1 | ['customer'] |
| DKS | DICK'S Sporting Goods, Inc. | 50.00 | 2 | |
| IMMP | Immutep Limited | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| CBIH | Cannabis Bioscience International Holdings, Inc. | 50.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 50.00 | 2 | |
| EVFM | Evofem Biosciences, Inc. | 50.00 | 2 | |
| CORT | Corcept Therapeutics Incorporated | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 50.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 50.00 | 2 | |
| GYRE | Gyre Therapeutics, Inc. | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 | |
| BBVA | Banco Bilbao Vizcaya Argentaria, S.A. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| ADAG | Adagene Inc. | 50.00 | 2 | |
| ORANY | ORANGE | 50.00 | 2 | |
| NAMSW | NewAmsterdam Pharma Co N.V. | 50.00 | 2 | |
| AVIR | Atea Pharmaceuticals, Inc. | 50.00 | 2 |